The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Open accessAbstract
BACKGROUND: There is evidence that medications or vitamins that increase the levels of brain catecholamines and protect against oxidative damage may reduce the neuronal damage and slow the progression of Alzheimer's disease. METHODS: We conducted a double-blind, placebo-controlled, randomized, multicenter trial in patients with Alzheimer's disease of moderate severity. A total of 341 patients received the selective monoamine oxidase inhibitor selegiline (10 mg a day), alpha-tocopherol (vitamin E, 2000 IU a day), both selegiline and alpha-tocopherol, or placebo for two years. The primary outcome was the time to the occurrence of any of the following: death, institutionalization, loss of the ability to perform basic activities of daily living, or severe dementia (defined as a Clinical Dementia Rating of 3). RESULTS: Despite random assignment, the baseline score on the Mini-Mental State Examination was higher in the placebo group than in the other three groups, and this variable was highly predictive of the primary outcome (P<0.001). In the unadjusted analyses, there was no statistically significant difference in the outcomes among the four groups. In analyses that included the base-line score on the Mini-Mental State Examination as a covariate, there were significant delays in the time to the primary outcome for the patients treated with selegiline (median time, 655 days; P=0.012), alpha-tocopherol (670 days, P=0.001) or combination therapy (585 days, P=0.049), as compared with the placebo group (440 days). CONCLUSIONS: In patients with moderately severe impairment from Alzheimer's disease, treatment with selegiline or alpha-tocopherol slows the progression of disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“To date, none of the tested compounds have proven effective (Sano et al., 1997; Petersen et al., 2005; Pham and Plakogiannis, 2005; DeKosky et al., 2008).”
From The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease (2011) · cites this paper as Sano et al., 1997
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Following a report of success of high-dose vitamin E in keeping late-stage AD patients out of long-term care facilities longer than patients on a placebo81, other studies with vitamin E have been less impressive70,78,80.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [81]
Experimental — accuracy not yet measuredIn the citing paper
“there were no concerning safely signals or increased mortality with high-dose vitamin E. 127,128”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [127]
In the citing paper
“high-dose vitamin E (1000 IU twice daily was the regimen tested) may be considered based on results of 2 RCTs that supported approximately 20% lower rate of ADL decline over approximately 2 to 3 years; there were no concerning safely signals or increased mortality with high-dose vitamin E. 127,128”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Blessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117
Pryor, W. A. (1976) · Cited by 1,876
Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease.
Smith, C. D., Carney, J. M., Starke-Reed, P. E., Oliver, C. N., Stadtman, E. R., Floyd, R. A., & Markesbery, W. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10540 · Cited by 1,296
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group (1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,222
A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease
Knapp, M. J. (1994) · JAMA · doi:10.1001/jama.271.13.985 · Cited by 1,000
The Free Radical Theory of Aging
Harman, D. (2003) · Antioxidants and Redox Signaling · doi:10.1089/152308603770310202 · Cited by 935
Research works printed but not linked: 1
- Holm S, 1979, Scand J Stat, 6, 65
Cited by
Sorted by citations
Items 701–800 of 1,005
Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
Evans, J. R., & Lawrenson, J. G. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000253.pub3 · Cited by 71
Is antioxidant use protective of cognitive function in the community-dwelling elderly?
Gray, S. L., Hanlon, J. T., Landerman, L. R., Artz, M., Schmader, K. E., & Fillenbaum, G. G. (2003) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/s1543-5946(03)80011-9 · Cited by 70
Antioxidants and Cognitive Function
Meydani, M. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.2001.tb05505.x · Cited by 70
Montiel, T., Quiroz‐Baez, R., Massieu, L., & Arias, C. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.02.126 · Cited by 70
Vitamin E Forms in Alzheimer's Disease: A Review of Controversial and Clinical Experiences
Usoro, O. B., & Mousa, S. A. (2010) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408390802304222 · Cited by 70
Clinical practice guidelines for severe Alzheimer's disease
Herrmann, N., Gauthier, S. G., & Lysy, P. G. (2007) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2007.07.007 · Cited by 70
Pham, D. Q., & Plakogiannis, R. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1g271 · Cited by 70
Longitudinal Assessment of Patient Dependence in Alzheimer Disease
Brickman, A. M., Riba, A., Bell, K. L., Marder, K. S., Albert, M., Brandt, J., & Stern, Y. (2002) · Archives of Neurology · doi:10.1001/archneur.59.8.1304 · Cited by 70
Dietary interventions in mild cognitive impairment and dementia
Vlachos, G. S., & Scarmeas, N. (2019) · Phlebolymphology · doi:10.31887/dcns.2019.21.1/nscarmeas · Cited by 70
Oxidative stress in mild cognitive impairment and Alzheimer disease: A continuum
Mecocci, P. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6207 · Cited by 70
Protective Activity of Aromatic Amines and Imines against Oxidative Nerve Cell Death
Moosmann, B., Skutella, T., Beyer, K., & Behl, C. (2001) · Biological Chemistry · doi:10.1515/bc.2001.195 · Cited by 70
Prasad, K. N., Cole, W. C., Hovland, A. R., Prasad, K. C., Nahreini, P., Kumar, B., Edwards‐Prasad, J., & Andreatta, C. P. (1999) · Current Opinion in Neurology · doi:10.1097/00019052-199912000-00017 · Cited by 70
Carnosine's Effect on Amyloid Fibril Formation and Induced Cytotoxicity of Lysozyme
Wu, J. W., Liu, K.-N., How, S.-C., Chen, W., Lai, C.-M., Liu, H.-S., Hu, C., & Wang, S. S. ‐. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081982 · Cited by 69
Role of antioxidants and a nutrient rich diet in Alzheimer's disease
Veurink, G., Perry, G. L., & Singh, S. K. (2020) · Open Biology · doi:10.1098/rsob.200084 · Cited by 69
Superoxide mediates the cell-death-enhancing action of presenilin-1 mutations
Guo, Q., Fu, W., Holtsberg, F. W., Steiner, S. M., & Mattson, M. P. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19990601)56:5 · Cited by 69
Nutritional Factors and Alzheimer's Disease
Reynish, W., Andrieu, S., Nourhashémi, F., & Vellas, B. J. (2001) · The Journals of Gerontology Series A · doi:10.1093/gerona/56.11.m675 · Cited by 69
Naeini, A. A., Elmadfa, I., Djazayery, A., Barekatain, M., Aghaye-Ghazvini, M. R., Djalali, M., & Feizi, A. (2013) · European Journal of Nutrition · doi:10.1007/s00394-013-0628-1 · Cited by 68
Pharmacological treatment of Alzheimer’s Disease
Bianchetti, A., Ranieri, P., Margiotta, A., & Trabucchi, M. (2006) · Aging Clinical and Experimental Research · doi:10.1007/bf03327433 · Cited by 68
An update on huperzine A as a treatment for Alzheimer's disease
Little, J. T., Walsh, S. P., & Aisen, P. S. S. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.2.209 · Cited by 68
Roles of Vitamins E and C on Neurodegenerative Diseases and Cognitive Performance
Martín, A., Youdim, K. A., Szprengiel, A., Shukitt‐Hale, B., & Joseph, J. A. (2002) · Nutrition Reviews · doi:10.1301/002966402320583433 · Cited by 68
Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development
Cutler, N. R., & Sramek, J. J. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(00)00147-0 · Cited by 68
Amyloid-β Metal Interaction and Metal Chelation
Cuajungco, M. P., Frederickson, C. J., & Bush, A. I. (2006) · Springer eBooks · doi:10.1007/0-387-23226-5_12 · Cited by 68
Essa, M. M., Braidy, N., Awlad-Thani, K., Vaishnav, R., Al-Asmi, A. R., Guillemin, G. J., Al‐Adawi, S., & Subash, S. (2015) · Journal of Ayurveda and Integrative Medicine · doi:10.4103/0975-9476.159073 · Cited by 67
Mild Cognitive Impairment: Potential Pharmacological Treatment Options
Sherwin, B. B. (2000) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2000.tb04703.x · Cited by 67
Ringheim, G. E., & Conant, K. E. (2003) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2003.10.013 · Cited by 67
Alkhalifa, A. E., Alkhalifa, O., Durdanovic, I., Ibrahim, D. R., & Maragkou, S. (2025) · Journal of Dementia and Alzheimer's Disease · doi:10.3390/jdad2020017 · Cited by 66
Neuroprotective Actions of Dipyridamole on Cultured CNS Neurons
Farinelli, S. E., Greene, L. A., & Friedman, W. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-14-05112.1998 · Cited by 66
Hypometabolism, Alzheimer’s Disease, and Possible Therapeutic Targets: An Overview
Raut, S., Bhalerao, A., Powers, M., Gonzalez, M., Mancuso, S., & Cucullo, L. (2023) · Cells · doi:10.3390/cells12162019 · Cited by 65
Shea, T. B., & Rogers, E. J. (2002) · Molecular Brain Research · doi:10.1016/s0169-328x(02)00412-6 · Cited by 65
Vitamin E Supplementation in the Prevention of Coronary Heart Disease
Pruthi, S., Allison, T. G., & Hensrud, D. D. (2001) · Mayo Clinic Proceedings · doi:10.4065/76.11.1131 · Cited by 65
Psychosocial competence of unselected young adults with sex chromosome abnormalities
Bender, B. G., Harmon, R. J., Linden, M. G., Bucher‐Bartelson, B., & Robinson, A. (1999) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19990416)88:2 · Cited by 61
Alzheimer's Disease: Role of Aging in Pathogenesis
Harman, D. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb02109.x · Cited by 65
Sultana, R., Baglioni, M., Cecchetti, R., Cai, J., Klein, J. B., Bastiani, P., Ruggiero, C., Mecocci, P., & Butterfield, D. A. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.08.001 · Cited by 64
Inhibition of GTRAP3-18 May Increase Neuroprotective Glutathione (GSH) Synthesis
Aoyama, K., & Nakaki, T. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms130912017 · Cited by 64
Pohanka, M. (2011) · Journal of Applied Biomedicine · doi:10.2478/v10136-011-0003-6 · Cited by 64
Hirvonen, J., Kailajärvi, M., Haltia, T., Koskimies, S., Någren, K., Virsu, P., Oikonen, V., Sipilä, H. T., Ruokoniemi, P. T., Virtanen, K. A., et al. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.241 · Cited by 64
Evaluation and Management of the Elderly Patient Presenting with Cognitive Complaints
Hildreth, K. L., & Church, S. D. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.11.006 · Cited by 66
Torika, N., Asraf, K., Roasso, E., Danon, A., & Fleisher‐Berkovich, S. (2016) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-016-9703-8 · Cited by 64
Designing a Brief Alzheimer Screen (BAS)
Mendiondo, M. S., Ashford, J. W., Kryscio, R. J., & Schmitt, F. A. (2003) · Journal of Alzheimer s Disease · doi:10.3233/jad-2003-5506 · Cited by 64
Review on anti-alzheimer drug development: approaches, challenges and perspectives
Abdallah, A. E. (2024) · RSC Advances · doi:10.1039/d3ra08333k · Cited by 63
Nutritional management of older adults with cognitive decline and dementia
Ogawa, S. (2014) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.12252 · Cited by 63
Chakrabarti, S., Sinha, M., Thakurta, I. G., Banerjee, P., & Chattopadhyay, M. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990152 · Cited by 63
Vitamin E in aging persons with Down syndrome
Sano, M. C., Aisen, P. S. S., Andrews, H., Tsai, W., Lai, F., Dalton, A. J., McCallion, P., Zendell, A. L., Mintz, M., Young, J. M., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002714 · Cited by 63
Self-citationBurke, W. J., Kristal, B. S., Yu, B. P., Li, S. W., & Lin, T. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01488-1 · Cited by 63
Early Intervention Is Key to Successful Management of Alzheimer Disease
DeKosky, S. T. (2003) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200307004-00004 · Cited by 63
Zheng, H., Amit, T., Bar‐Am, O., Fridkin, M., Youdim, M. B. H., & Mandel, S. A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120013 · Cited by 62
Arnim, C. A. F. V., the ActiFE Ulm study group, Herbolsheimer, F., Nikolaus, T., Peter, R., Biesalski, H. K., Ludolph, A. C., Riepe, M. W., & Nagel, G. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120634 · Cited by 62
Vitamin E and memantine in Alzheimer's disease: Clinical trial methods and baseline data
Dysken, M. W., Guarino, P., Vertrees, J. E., Asthana, S., Sano, M. C., Llorente, M. D., Pallaki, M., Love, S. B., Schellenberg, G. D., McCarten, J. R., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.01.014 · Cited by 62
Self-citationMore than the sum of its parts? Nutrition in Alzheimer's disease
Arnim, C. A. F. V., Gola, U., & Biesalski, H. K. (2010) · Nutrition · doi:10.1016/j.nut.2009.11.009 · Cited by 62
Circulating vitamin E levels and Alzheimer's disease: a Mendelian randomization study
Liu, G., Zhao, Y., Jin, S., Hu, Y., Wang, T., Tian, R., Han, Z., Xu, D., & Jiang, Q. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.08.008 · Cited by 62
Alzheimer’s disease and Alzheimer’s dementia: distinct but overlapping entities
Blass, J. P. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00036-2 · Cited by 62
Martin, A., Janigian, D., Shukitt‐Hale, B., Prior, R. L., & Joseph, J. A. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01923-x · Cited by 62
Rockwood, K. J., & MacKnight, C. (2001) · Neuroepidemiology · doi:10.1159/000054761 · Cited by 62
Strategies, Development, and Pitfalls of Therapeutic Options for Alzheimer's Disease
Haas, C. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110986 · Cited by 61
Jeong, H. Y., Kim, J. Y., Lee, H. K., Ha, D. T., Song, K., Bae, K., & Seong, Y. H. (2010) · Archives of Pharmacal Research · doi:10.1007/s12272-010-1015-6 · Cited by 61
Stough, C. K. K., Pase, M. P., Cropley, V., Myers, S. P., Nolidin, K., King, R., Camfield, D., Wesnes, K. A., Pipingas, A., Croft, K. D., et al. (2012) · Nutrition Journal · doi:10.1186/1475-2891-11-11 · Cited by 61
Jain, S., Sangma, T., Shukla, S. K., & Mediratta, P. K. (2014) · Nutritional Neuroscience · doi:10.1179/1476830514y.0000000113 · Cited by 61
Facheris, M., Beretta, S., & Ferrarese, C. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6210 · Cited by 61
Realistic Expectations: The Management of Severe Alzheimer Disease
Bullock, R. A., & Hammond, G. (2003) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200307003-00004 · Cited by 61
Caregivers’ preferences for the treatment of patients with Alzheimer’s disease
Karlawish, J. H., Klocinski, J., Merz, J. F., Clark, C. M., & Asch, D. A. (2000) · Neurology · doi:10.1212/wnl.55.7.1008 · Cited by 61
Amyloid β-peptide induces cholinergic dysfunction and cognitive deficits: a minireview
Tran, M. H., Yamada, K., & Nabeshima, T. (2002) · Peptides · doi:10.1016/s0196-9781(02)00062-1 · Cited by 61
Prevention of Type I Diabetes by Low-Dose Gamma Irradiation in NOD Mice
Takahashi, M., Kojima, S., Yamaoka, K., & Niki, E. (2000) · Radiation Research · doi:10.1667/0033-7587(2000)154[0680:potidb]2.0.co;2 · Cited by 61
Morris, J. C. (2005) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000167923.56275.d8 · Cited by 61
Wilcock, G. K., Birks, J., Whitehead, A., & Evans, S. J. G. (2002) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.545 · Cited by 61
The Neurobiology and Pharmacotherapy of Alzheimer's Disease
Félician, O., & Sandson, T. A. (1999) · Journal of Neuropsychiatry · doi:10.1176/jnp.11.1.19 · Cited by 61
Guan, J.-Z., Guan, W.-P., Maeda, T., & Makino, N. (2011) · Gerontology · doi:10.1159/000327821 · Cited by 60
Shinohara, M., Sato, N., Shimamura, M., Kurinami, H., Hamasaki, T., Chatterjee, A., Rakugi, H., & Morishita, R. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00071 · Cited by 60
Brambilla, D., Verpillot, R., Taverna, M., Kimpe, L. D., Droumaguet, B. L., Nicolas, J., Canovi, M., Gobbi, M., Mantegazza, F., Salmona, M., et al. (2010) · Analytical Chemistry · doi:10.1021/ac102045x · Cited by 59
Unleashing the untold and misunderstood observations on vitamin E
Gee, P. T. (2010) · Genes & Nutrition · doi:10.1007/s12263-010-0180-z · Cited by 60
McGhee, D. J. M., Ritchie, C. W., Zajicek, J., & Counsell, C. E. (2016) · BMC Neurology · doi:10.1186/s12883-016-0606-3 · Cited by 60
Effects of dietary RRR α-tocopherol vs all-racemic α-tocopherol on health outcomes
Ranard, K. M., & Erdman, J. W. (2017) · Nutrition Reviews · doi:10.1093/nutrit/nux067 · Cited by 60
Alagiakrishnan, K., McCracken, P., & Feldman, H. (2006) · Postgraduate Medical Journal · doi:10.1136/pgmj.2005.035030 · Cited by 60
The link between cholesterol and Alzheimer's disease
Sjögren, M. J. C., & Blennow, K. (2005) · The World Journal of Biological Psychiatry · doi:10.1080/15622970510029795 · Cited by 60
Free radicals in Alzheimer’s dementia: currently available therapeutic strategies
Rösler, M., Retz, W., Thome, J., & Riederer, P. F. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-7508-8_21 · Cited by 60
Oxidative Stress in Tauopathies: From Cause to Therapy
Bartolomé, F. B., Carro, E., & Alquézar, C. (2022) · Antioxidants · doi:10.3390/antiox11081421 · Cited by 59
Mechanistic insights and emerging therapeutic stratagems for Alzheimer’s disease
Rajendran, K., & Krishnan, U. M. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102309 · Cited by 59
Vitamins E and C pretreatment prevents ovariectomy-induced memory deficits in water maze
Monteiro, S. C., Matté, C., Bavaresco, C. S., Netto, C. A., & Wyse, Â. T. D. S. (2005) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2005.08.002 · Cited by 59
Yabuta, Y., Tanaka, H., Yoshimura, S., Suzuki, A., Tamoi, M., Maruta, T., & Shigeoka, S. (2012) · Transgenic Research · doi:10.1007/s11248-012-9656-5 · Cited by 59
Zicker, S. C., Jewell, D. E., Yamka, R. M., & Milgram, N. W. (2012) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.241.5.583 · Cited by 59
Lipophilic antioxidants in neurodegenerative diseases
Chang, K., Cheng, M., Chiang, M.-C., & Chen, C. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.06.031 · Cited by 59
Sang, Z., Wang, K., Shi, J., Liu, W., & Tan, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.026 · Cited by 59
Solfrizzi, V., Colacicco, A. M., D’Introno, A., Capurso, C. A., Parigi, A. D., Capurso, S. A., Torres, F., Capurso, A., & Panza, F. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-102-314 · Cited by 59
ApoE-Dependent Plasticity in Alzheimer's Disease
Teter, B. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:3:167 · Cited by 59
Uptake of Lipoprotein‐Associated α‐Tocopherol by Primary Porcine Brain Capillary Endothelial Cells
Goti, D., Hammer, A., Galla, H., Malle, E., & Sattler, W. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741374.x · Cited by 59
Rosenheck, R. A. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.11.1259 · Cited by 59
Jialal, I., Traber, M. G., & Devaraj, S. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200102000-00009 · Cited by 59
The Antioxidant Vitamins C and E
Packer, L. (2003) · AOCS Publishing eBooks · doi:10.4324/9780429270710 · Cited by 59
Why Vitamin E Therapy Fails for Treatment of Alzheimer's Disease
Brewer, G. J. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1238 · Cited by 58
Liu, Q. F., Lee, J. H., Kim, Y., Lee, S., Hong, Y. K., Hwang, S., Oh, Y., Lee, K., Yun, H. S., Lee, I., et al. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b15-00459 · Cited by 58
For the Select Investigators, Kryscio, R. J., Abner, E. L., Schmitt, F. A., Goodman, P. J., Mendiondo, M. S., Caban‐Holt, A., Dennis, B., Mathews, M. J., Klein, E. A., et al. (2012) · The journal of nutrition health & aging · doi:10.1007/s12603-012-0083-3 · Cited by 58
Clinical Trials in Predementia Stages of Alzheimer Disease
Pillai, J. A., & Cummings, J. L. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2013.01.002 · Cited by 58
Epidemiology, Assessment, and Treatment of Dementia
Nowrangi, M. A., Rao, V., & Lyketsos, C. G. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.02.004 · Cited by 58
Pandareesh, M. D., Anand, T., & Khanum, F. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1780-1 · Cited by 58
Dual Inhibitors of Cholinesterases and Monoamine Oxidases for Alzheimer’S Disease
Knez, D., Sova, M., Košak, U., & Gobec, S. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0036 · Cited by 58
Woo, J. (2000) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1601036 · Cited by 58
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's Disease Trial
Schneider, L. S. S., Ismail, M. S., Dagerman, K., Davis, S. M., Olin, J. T., McManus, D., Pfeiffer, E., Ryan, J. M., Sultzer, D. L., & Tariot, P. N. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006991 · Cited by 58
Self-citationCartford, M. C., Gemma, C., & Bickford, P. C. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-14-05813.2002 · Cited by 58
Reliability of monitoring the clinical dementia rating in multicenter clinical trials.
Schafer, K. A., Tractenberg, R. E., Sano, M., Mackell, J. A., Thomas, R. G., Gamst, A. C., Thal, L. J., & Morris, J. C. (2004) · PubMed · Cited by 58
Self-citationWoltjer, R. L., Nghiem, W., Maezawa, I., Milatović, D., Vaisar, T., Montine, K. S., & Montine, T. J. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03109.x · Cited by 58
Current pharmacologic options for patients with Alzheimer's disease
Reichman, W. E. (2003) · Annals of General Hospital Psychiatry · doi:10.1186/1475-2832-2-1 · Cited by 58
Metadata
- Authors
- Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., Schneider, L. S., & Thal, L. J.
- Affiliations
- University of California San Diego (US)
- Harvard University (US)
- University of California, Irvine (US)
- University of South Florida (US)
- University of Southern California (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1997-04-24
- Volume
- 336
- Issue
- 17
- Pages
- 1216-1222
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2326200998
- Cited by
- 2,380
- References
- 36
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 39 · 2023: 39 · 2022: 41 · 2021: 38 · 2020: 44 · 2019: 43 · 2018: 44 · 2017: 47 · 2016: 55 · 2015: 54 · 2014: 72 · 2013: 62 · 2012: 82
- FWCI
- 118.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (U01‐AG10483, U01AG010483, U19AG010483)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, selegiline, alpha-tocopherol, vitamin E, monoamine oxidase inhibitors, combination therapy, disease progression, dementia, activities of daily living, Mini-Mental State Examination, oxidative stress, catecholamines
- MeSH terms
- Activities of Daily Living, Aged, Alzheimer Disease, Cognition, Double-Blind Method, Drug Combinations, Female, Humans, Institutionalization, Male, Mental Status Schedule, Monoamine Oxidase Inhibitors, Selegiline, Vitamin E, Proportional Hazards Models, Treatment Outcome, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
